Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

অনুরূপ উপাদানগুলি

• Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
  অনুযায়ী: Lumry, William R., অন্যান্য
  প্রকাশিত: (2021)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  অনুযায়ী: Li, H. Henry, অন্যান্য
  প্রকাশিত: (2019)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  অনুযায়ী: H. Henry Li, অন্যান্য
  প্রকাশিত: (2019-08-01)
• Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
  অনুযায়ী: Busse, Paula J., অন্যান্য
  প্রকাশিত: (2018)
• Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
  অনুযায়ী: Riedl, Marc A., অন্যান্য
  প্রকাশিত: (2020)